PHLDA3 acts as a key inhibitor of the epithelial–mesenchymal transition (EMT) and tumor progression, including metastasis, by modulating the Phosphoinositide 3-kinases/Protein kinase B (PI3K/AKT) signaling pathway. Here, AKT1 is linked to neoplasm.